Evidence map›Paper›PMID 40814366›Full record

ArticleAmerican journal of cancer research2025

The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence.

I-Ting Chen, Hsu-Ching Huang, Chi-Lu Chiang, Chia-I Shen, Yen-Han Tseng, Ying-Ting Liao, Yuh-Min Chen, Yung-Hung Luo

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

I-Ting ChenDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Hsu-Ching HuangDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Chi-Lu ChiangDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Chia-I ShenDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Yen-Han TsengDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Ying-Ting LiaoDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Yuh-Min ChenDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.
Yung-Hung LuoDepartment of Chest Medicine, Taipei Veterans General Hospital Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line treatment for advanced MATERIALS AND

methodsA retrospective analysis was performed to assess the outcomes for patients with

resultsThis study enrolled 107 patients with advanced

conclusionThis study highlights the potential benefits of early initiation of IO-based regimens in advanced

Indexed as

Epidermal growth factor receptorimmunotherapynon-small cell lung cancertyrosine kinase inhibitors

Identifiers

PMID40814366
PMCPMC12344174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.